ADIPOQ and Insulin resistance: In addition, numerous experimental and clinical observations have shown decreased adiponectin bioactivity in obesity and obesity-related complications, including insulin resistance, diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease (Shehzad et al., 2012).